Tower Research Capital (TRC)’s Regencell Bioscience RGC Stock Holding History

Tower Research Capital (TRC)’s Portfolio RGC Stock Details RGC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1	Closed	-$25	–	5563
2026 Q1	$25	Buy	+1	New	+$28	﹤0.01%	5055
2025 Q4	–	Sell	-357	Closed	-$5.52K	–	5510
2025 Q3	$5.52K	Buy	+357	New	+$5.12K	﹤0.01%	4230
2025 Q2	–	Sell	-26,524	Closed	-$22.3K	–	5524
2025 Q1	$22.3K	Buy	+26,524	New	+$7.33K	﹤0.01%	2860
2023 Q4	–	Sell	-3,230	Closed	-$1.19K	–	6136
2023 Q3	$1.19K	Buy	+3,230	New	+$1.34K	﹤0.01%	5385
2023 Q2	–	Sell	-7,600	Closed	-$5K	–	6314
2023 Q1	$5K	Buy	+7,600	New	+$5.6K	﹤0.01%	4988
2022 Q4	–	Sell	-14,136	Closed	-$12K	–	6287
2022 Q3	$12K	Sell	14,136 -7,828	-36%	-$6.85K	﹤0.01%	4365
2022 Q2	$20K	Buy	21,964 +5,548	+34%	+$4.18K	﹤0.01%	3802
2022 Q1	$10K	Buy	+16,416	New	+$14.1K	﹤0.01%	4335
2021 Q4	–	Sell	-124,260	Closed	-$74K	–	6501
2021 Q3	$74K	Buy	+124,260	New	+$56.1K	﹤0.01%	2661

Other funds holding RGC

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

Amundi Paris, France $416B AUM 44.19% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return

Tower Research Capital (TRC)'s RGC Position: Q2 2026 in Review

Tower Research Capital (TRC) sold out of Regencell Bioscience (RGC) in Q2 2026, closing a stake of 1 share — an estimated $25 sold.

Tower Research Capital (TRC) first reported a position in RGC in Q3 2021 and held it in 9 quarters. The position peaked at $74K in Q3 2021. 35 funds tracked by Wall St. Rank hold RGC as of Q2 2026.

Tower Research Capital (TRC) reported no remaining Regencell Bioscience position as of Q2 2026 after selling out during the quarter.
Tower Research Capital (TRC) sold 1 Regencell Bioscience share in Q2 2026, an estimated $25.
Tower Research Capital (TRC) first reported a position in Regencell Bioscience in Q3 2021 and held it in 9 quarters.
Tower Research Capital (TRC)'s Regencell Bioscience position peaked at $74K in Q3 2021.
35 funds tracked by Wall St. Rank held Regencell Bioscience as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.